Q3 2025 Bruker Corp Earnings Call

Frank Laukien: We will now begin the question and answer session. To ask a question, you may press star then one on your touchstone phone. If you're using a speakerphone, please take up the handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star and then two. Our first question comes from Puneet Souda with Leerink Partners. Please go ahead. Yeah, hi, Frank. Thanks for taking my questions here. First one on the book-to-bill, good to see more than one and congrats on the quarter. Just given the order momentum you're seeing here, but just wondering, how has that trended in fourth quarter? Are you continuing to see the mid-teens organic order growth here? And maybe could you elaborate a bit, just a number of moving parts here? How has the international momentum continued?

Ignite conference specialist by pressing the star key followed by zero.

After todays presentation, there will be an opportunity to ask questions to ask a question you May Press Star then one on your Touchtone phone to withdraw your question. Please press star and then to.

Also please limit yourself to one question and one follow up.

Please note this event is being recorded.

I'd now like to turn conference over to Joe Costa Director of broker Investor Relations. Please go ahead.

Good morning, I would like to welcome everyone to broker Corporation's third quarter 2025 earnings Conference call. My name is Joe Costco and I am the director of broker Investor Relations. Joining me on today's call are our president and CEO, Frank locking in our EVP and CFO Gerald Herman.

In addition to the earnings release, we issued earlier today during today's conference call, we will be referencing a slide presentation that can be downloaded from the events and presentation section of brokers Investor Relations website.

Frank Laukien: Is it more active versus pharma? And maybe tell us a bit more on the academic side of the US. Are you starting to see some recovery there? Given the points you mentioned, DNP and a couple of other points you mentioned in the slide. Yes. Thank you very much, Puneet. We really don't have Q4 data yet. It's too early. I just can't comment on Q4. There's no meaningful data available yet. Moving parts, ACAGAV. The strength in ACAGAV orders was. Primarily outside of the US, but the US were less weak. All right, less soft. Is that a word? Anyway, Q3 was better in the US for ACAGAV orders than Q2, and we saw some orders come through. I gave you some NMR examples, but of course, it was broader than that. Also included timsTOF and microscopes and other stuff.

During today's call, we will be highlighting non-GAAP financial information.

Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at IR dot broker dot com.

Before we begin I would like to reference brokers Safe Harbor statement, which is shown on slide two of the presentation.

During this conference call, we will make forward looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to acquisitions geopolitical risks tariffs foreign currency market demand or supply chains.

The company's actual results may differ materially from such statements factors that might cause such differences include but are not limited to those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2024 as updated by our other SEC filings, which are available on our website and on.

Speaker #1: Good Good day and welcome to the BRUKER CORPERATION 3rd QUARTER 2025 EARNINGS CONFERENCE CALL. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.

On the Sec's website.

Also please note that the following information is based on current business conditions and on our outlook as of today November three 2025.

Speaker #1: After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone.

Frank Laukien: They're hard to say what's the trend in the US because they're clearly in the US. There was a little bit of catch-up in Q3 compared to Q2 and maybe even Q1 in ACAGAV orders in Europe and Japan, and a little bit in China also. That's why they might be green shoots, were quite encouraging, and that's why our ACAGAV orders year over year were up considerably in Q3. Don't think that we're now in a high teens growth trend all of a sudden. That's just a quarter, and Q3 2024 was not the strongest. Anyway, it was very encouraging, and we hope that will continue in Q4, but I wouldn't. Yeah, the activity and opportunities are great and are encouraging, but I wouldn't read anything into that yet. Just too early to comment on Q4.

We do not intend to update our forward looking statements based on new information future events or for other reasons, except as may be required by law prior to the release of our fourth quarter and full year 2025 financial results expected in February 2026.

Speaker #1: To withdraw your question, please press star and then two. Also, please limit yourself to one question and one follow-up. Please note this event is being recorded.

Speaker #1: I would now like to turn the conference over to Joe Kostka. Director of BRUKER Investor Relations. Please go ahead.

You should not rely on these forward looking statements as necessarily representing our views or outlook as of any after today.

Speaker #2: Good Good morning. I would like to welcome everyone to BRUKER CORPERATION's 3rd QUARTER 2025 EARNINGS CONFERENCE CALL. My name is Joe Kostka, and I am the Director of BRUKER Investor Relations.

We will begin today's call with Frank providing an overview of our business progress and <unk>.

Gerald will then cover the financials for the third quarter of 2025 in more detail and share our updated full year 2025 financial outlook.

Speaker #2: Joining me on today's call are our President and CEO, Frank Laukien, and our EVP and CFO, Gerald Herman. In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the events and presentations section of BRUKER's Investor Relations website.

Now I'd like to turn the call over to brokers CEO Frank logging.

Thank you Joe and good morning, everyone and thank you for joining us on today's third quarter 2025 earnings call.

Frank Laukien: We do need Q4 to then give more meaningful growth and margin numbers for 2026. We're not going to do that today. We're not able to do that today until we really see how Q4 comes in, particularly the orders, obviously. To the other moving pieces, Puneet, yes, biopharma has been reasonable in or okay, not great, but okay in the first half of the year, much better in the third half of the year in terms of orders. A particular strength there in the US, but also outside of the US, but ACAGAV, sorry, biopharma particularly in the US. The applied market strength, which is a good sign of macroeconomic trends, that had a pretty broad international distribution. I don't know that I would highlight any geography there. That may add some color to the admittedly multiple moving pieces.

As forecasted our third quarter revenues and earnings were down year over year, primarily due to weaker academic and research instruments demand in the first half of 2025.

Speaker #2: During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com.

However, our Q3 25 performance was quite a bit better than expected and represents a meaningful sequential step up from our Q2 performance.

Speaker #2: Before we begin, I would like to reference BRUKER's safe harbor statement, which is shown on slide two of the presentation. During this conference call, we will make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties.

In this in this third quarter, we were encouraged by our mid single digit percentage organic bookings growth for the first time. This year, we saw strength in bookings in the academic government market segments, as well as improving biopharma and applied market orders.

Speaker #2: Including those related to acquisitions, geopolitical risks, tariffs, foreign currency, market demand, or supply chains. The company's actual results may differ materially from such statements.

Interestingly.

Speaker #2: Factors that might cause such differences include but are not limited to those discussed in today's earnings release and in our Form 10-K for the period ending December 31st, 2024, as updated by our other SEC filings, which are available on our website and on the SEC's website.

Q3 of 25% we saw the Stark contrast of a double digit percentage organic revenue decline in the ACA golf markets year over year compared to a double digit percentage organic improvement in <unk> Gov bookings year over year.

Frank Laukien: The effect of Bruker, that prior order weakness now shows up in the P&L, whereas the new order improvements and encouragement, and maybe it is momentum if Q4 goes well, it's more likely to show it will show up all in 2026. Hope that helps. Got it. That's very helpful. Anything on the ultra-high field gigahertz-class NMRs, how are you thinking about those? Obviously, tougher comp in the third quarter, but as you go into 2026, how is the momentum there? I know we've been waiting for US to acquire more of those instruments. Thank you. Yeah, the US is the enigma there, but obviously, there's also other geographies. I still can't call the US trends. Obviously, nothing has come through so far, so we'll see. We're expecting at least one order for the gigahertz-class in Q4, not in the US. There's a number of cases.

Speaker #2: Also, please note that the following information is based on current business conditions and on our outlook as of today, November 3rd, 2025. We do not intend to update our forward-looking statements based on new information, future events, or for other reasons except as may be required by law prior to the release of our fourth quarter and full year 2025 financial results expected in February 2026.

In fact, our ACA Gov orders grew in the high teens percentage in Q3 25.

As very robust order growth outside of the United States more than offset a continued year over year softness in the U S.

A lot of moving pieces.

Any way, notably our innovative spatial biology, proteomics and multi Omics solutions launched at Hebt ACR and ASN. Miss earlier. This year are being very well received by our biopharma and academic customers and enhance our leadership and enabling tools for drug discovery.

Speaker #2: You should not rely on these forward-looking statements as necessarily representing our views or outlook as of any date after today. We will begin today's call with Frank providing an overview of our business progress.

Speaker #2: Gerald will then cover the financials for the third quarter of 2025 in more detail and share our updated full year 2025 financial outlook. Now, I'd like to turn the call over to BRUKER CEO, Frank Laukien.

<unk> and disease Biology research in the post genomic era.

Biopharma and applied also saw organic bookings growth in Q3 with Biopharma, having the strongest organic order growth of all of our end markets. Both in Q3 and year to date.

Speaker #3: Thank you, Joe. Good morning, everyone, and thank you for joining us on today's third quarter 2025 earnings call. As forecasted, our third quarter revenues and earnings were down year over year primarily due to weaker academic and research instruments demand in the first half of 2025.

Organic scientific instruments disorders and tying.

Frank Laukien: Brewing around the world, including in the US, but today is too early to do that. When we give guidance for 2026, and presumably in early February of 2026, we can also comment on what has come in or where we have clear line of sight for ultra-high field or for the gigahertz-class. Yes, nothing in revenue in Q3. We expect hopefully one order in Q4. Sometimes these things get delayed by a quarter. Anyway, it is just not such a big part of our business anymore. I know they are easier to count. Indeed, in Q3, a lot of our organic decline had to do with these two gigahertz-class systems in Q3 2024 revenue, which accounted for more than $25 million of our revenue and comes with nice operating profits and margins. It did have an effect on Q3. Anyway, that is the color I can give you.

Increased by double digit percentage in the third quarter year over year.

Speaker #3: However, our Q3 '25 performance was quite a bit better than expected, and represents a meaningful sequential step up from our Q2 performance. In this third quarter, we were encouraged by our mid-single-digit percentage organic bookings growth.

And we saw what may be green shoots of stimulus funding in China, beginning to be dispersed.

So this stronger Q3 dollars 25 order performance drove our scientific and scientific instruments segment book to Bill ratio greater than one point X greater than one point, though for the first time in several quarters.

Speaker #3: For the first time this year, we saw strength in bookings in the academic government market segment, as well as improving biopharma and applied market orders.

While one quarter of improved orders is too early to call. A trend. We are encouraged that our two divisions most directly tied to macroeconomic factors, which happens to be broker optics access also saw strong bookings in Q3 of 25. These two divisions often serve as a leading indicator within.

Speaker #3: Interestingly, in Q3 of '25, we saw the stark contrast of a double-digit percentage organic revenue decline in the ACAGAV markets year over year, compared to a double-digit percentage organic improvement in ACAGAV bookings year over year.

Broker for changing macro market trends.

However, due to the late timing of Q3 orders in certain customer sites delays, we are reducing our organic revenue growth expectations for the fourth quarter and our guidance for the full year.

Speaker #3: In fact, our ACAGAV orders grew in the high teens percentage in Q3 '25, as very robust order growth outside of the United States more than offset a continued year-over-year softness in the US.

Frank Laukien: More to come when we give guidance in early February. Got it. Thank you. The next question comes from Michael Ryskin with Bank of America. Please go ahead. Michael, your line may be on mute. Hi, this is Mike on for this event, gone for Mike. Could you give us the impact of the government shutdown that you are seeing in Q4, and is that baked into the updated outlook? Thank you. Well, that is a good question, and it is not formally baked into our outlook. So far, we have assumed that the effect will be relatively minor, but indeed, if this were to continue for a full second month or so, then this may delay some new grants, some orders. It could also delay some installations. So far, we have not become aware of anything that gets.

This also de risks our implied fourth quarter forecast to levels that we are very confident we can achieve.

Speaker #3: A lot of moving pieces. Anyway, notably, our innovative spatial biology, proteomics, and multiomic solutions launched at AGBT, AACR, and ASMS earlier this year are being very well received by our biopharma and academic customers.

Finally, our major cost finally on this slide our major cost savings initiatives announced last quarter are progressing very well towards the high end of our $110 million to $100 million $20 million cost down targets for 2026, and they are expected to.

Speaker #3: And enhance our leadership in enabling tools for drug discovery, and disease biology research in the post-genomic era. Biopharma and applied also saw organic bookings growth in Q3, with biopharma having the strongest organic order growth of all of our end markets, both in Q3 and year to date.

<unk> deliver significant margin expansion and double digit EPS growth in 2026.

Alright, turning to slide four now.

In Q3, 25 continued softness in <unk> Gov revenues led to year over year declines throughout the P&L. However.

However, we noted sequential improvements in Biopharma, and microbiology and diagnostic revenues, which led to both top and bottom line coming in better than our expectations in early August.

Speaker #3: Organic scientific instruments orders in China increased by double-digit percentage in the third quarter year over year, and we saw what may be green shoots of stimulus funding in China beginning to be dispersed.

Brokers Q3 dollars 25 reported revenues decreased half a percent to 865 million, which included a currency tailwind of two 9%.

Speaker #3: So this stronger Q3 '25 order performance drove our scientific instruments segment book-to-bill ratio to greater than 1.0x, greater than 1.0 for the first time in several quarters.

Frank Laukien: We think that our Q4 guidance is now appropriately conservative to absorb some of that and maybe what we have seen so far, but know if there was a further multi-week or multi-month shutdown, that could have additional impacts that are not presently in our guidance. Understood. Thank you. I know that you are not formally guiding on 2026 today, but you called out meaningful improvement versus the minus 4% to 5% organic in 2025. Is it fair to assume that you can grow revenues in 2026, or are we looking at flat year over year? Thank you. We are not making that assumption yet. It is a fair question, of course. We really do want to see our Q4 2025 bookings in order then to give hopefully reliable guidance in February of 2026. Yes, I mean, this year 2025, we are coming down organically quite a bit, right?

On an organic basis revenues decreased four 5%, which included a $5 four organic decline and scientific instruments and six 9% organic growth at best net of intercompany eliminations revenue growth from acquisitions added one one.

Speaker #3: While one quarter of improved orders is too early to call a trend, we are encouraged that our two divisions, most directly tied to macroeconomic factors, which happens to be BRUKER OPTICS and AXS, also saw strong bookings in Q3 of '25.

1%.

Our third quarter 25, non-GAAP operating margin was 12, 3% a decrease of 260 bps year over year as lower revenue absorption additional tariff costs and currency headwinds were only partially mitigated in Q3.

Speaker #3: These two divisions often serve as a leading indicator within BRUKER for changing macro market trends. However, due to the late timing of Q3 orders and certain customers' site delays, we are reducing our organic revenue growth expectations for the fourth quarter and our guidance for the full year.

Our earlier cost and pricing actions.

Our third quarter, 25% non-GAAP operating margin of 12, 3% represented a meaningful sequential improvement over the 9% we reported in the second quarter.

Speaker #3: This also derisks our implied fourth quarter forecast to levels that we are very confident we can achieve. Finally, our major cost, finally on this slide, our major cost savings initiatives announced last quarter are progressing very well.

Our third quarter diluted non-GAAP EPS was <unk> 45.

Down 25% from 60.

Speaker #3: Towards the high end of our $100 million to $102 million cost down targets for 2026, and they are expected to deliver significant margin expansion and double-digit EPS growth in 2026.

In Q3 of 2004.

But up sequentially compared to the 32, we reported in the second quarter of 'twenty five durable obviously discuss the drivers for margin and EPS later in more detail.

Frank Laukien: We undoubtedly can do much better than that next year, but we are not presently. I do not want to state any assumptions because then you will take them as guidance and they are not. We just want to make sure that with the significant cost cutting that we are doing, even without growth. Which is not our assumption, but even without growth, we can expand our operating profit margins very significantly, say 250 to 300 basis points or something like that. Yes, we expect, we continue to expect double-digit EPS growth, even after absorbing the roughly $0.20 dilution that Gerald mentioned during his prepared remarks for the additional dilution from the mandatory convert that we did in September. We still expect to do double-digit non-GAAP EPS growth next year. That is simply, mathematically, that is simply, we are not, this is without growth.

Moving to slide five our year to date Q3 revenue increased by three 8% to $2 5 billion organic revenue declined three 1% with a two 9% organic decline in scientific instruments and a five 5% organic decline at best net of <unk>.

Speaker #3: All right, turning to slide four now. In Q3 '25, continued softness in ACAGAV revenues led to year-over-year declines throughout the P&L. However, we noted sequential improvements in biopharma microbiology and diagnostic revenues, which led to both top and bottom line coming in better than our expectations in early August.

Intercompany eliminations.

Our first nine months 2025, non-GAAP gross and operating margin and GAAP and non-GAAP EPS performance are all summarized on slide five.

Speaker #3: BRUKER's Q3 2025 reported revenues decreased half a percent to $860.5 million, which included a currency tailwind of 2.9%. On an organic basis, revenues decreased 4.5%, which included a 5.4% organic decline in scientific instruments and 6.9% organic growth at best net of intercompany eliminations.

So please turn to slide six and seven where we highlight where we highlight the year to date.

Third quarter performance of our three scientific instruments group and of our best segment, all on a constant currency and year over year basis.

Year to date 2025 bio spin group.

<unk> revenue F $612 million was shown.

Frank Laukien: Without growth is not our preliminary guidance. Period. That is what we are looking at right now. Preliminary guidance for us right now on growth does not make sense until we have seen our Q4 orders for Bruker. That is going to be very important for next year. Thank you for the color. Thank you. The next question comes from Tycho Peterson with Jefferies. Please go ahead. Hey, thanks. Frank, I want to pick up on that margin point. It sounds like you are committing to this 300 basis points of margin expansion, even if the top line is flat.

Speaker #3: Revenue growth from acquisitions added 1.1%. Our third quarter 2025 non-GAAP operating margin was 12.3%, a decrease of 260 basis points year over year, as lower revenue absorption, additional tariff costs, and currency headwinds were only partially mitigated in Q3 by our earlier cost and pricing actions.

Excuse me was down mid single digits percentage.

<unk> saw growth in lab automation and services offset by a tough comparison with two gigahertz class <unk> EMR systems in Q3, 2004 revenue versus none in Q3 of 25.

<unk> saw weakness in <unk> Gov, and Biopharma revenues, but improved order growth in both end markets in the third quarter of 2005.

Speaker #3: Our third quarter 2025 non-GAAP operating margin of 12.3% represented a meaningful sequential improvement over the 9.0% we reported in the second quarter. Our third quarter diluted non-GAAP EPS was $0.45, down 25% from $0.60 in Q3 of 2024.

Year to date 2025, Calvert group revenue of $879 million increased in the low double digits percentage, driven by microbiology and infectious disease diagnostics.

Frank Laukien: I guess, given that you are running at the high end of the $100 to 120 million cost savings target in the near term, should we interpret the upper end of savings as simply kind of increasing confidence in hitting that margin target next year, or do you think you could potentially do better? Nice question, Tycho. I was not confirming a number. I know you have mentioned one. I am not saying take that number out of your model, but I am not confirming it either. I think the second part of your question, I think it is fair to say we hope to have increased confidence in getting to very significant margin expansion and double-digit EPS growth all in, including the MCP. That is exactly why we are driving towards the high end of our cost cutting target. You are spot on with that one.

With strength in both <unk> and the <unk> molecular diagnostics franchises.

Speaker #3: But up sequentially compared to the 32 cents we reported in the second quarter of '25. Gerald will obviously discuss the drivers for margin and EPS later in more detail.

Life Science mass spectrometry is seeing early traction for recently launched products, including the new team's omni and the new team's metabo both from launched at ASML.

Speaker #3: Moving to slide five, our year-to-date Q3 revenue increased by 3.0% to 2.5 billion. Organic revenue declined 3.1% with a 2.9% organic decline in scientific instruments, and a 5.5% organic decline at best net of intercompany eliminations.

While our molecular spectroscopy revenues remained stable, but with strong applied markets orders in Q3, 25 vessels mentioned earlier.

<unk> turn to slide seven now please.

Year to date 2025 broker nano revenue of $775 million declined in the low single digits percentage.

Speaker #3: Our first nine months 2025 non-GAAP gross and operating margin and GAAP and non-GAAP EPS performance are all summarized on slide five. So please turn to slide six and seven, where we highlight the year-to-date third quarter performance of our three scientific instruments group and of our best segment.

Revenues from advanced X-ray and nano allow nano analysis tools were down year over year at year, partially offset by growth in spatial biology.

Frank Laukien: Probing a little bit on your assumptions. We are not talking numbers for 2026, but just A&G, the outlook there, assuming flattish NIH budget. I mean, just talk a little bit about some of the give and takes around multi-year grants. I assume you are not expecting any budget flush here in the near term, but as we think about next year, do you think A&G orders will grow? Can you flush out your comments on China stimulus? How material was that, and how do you think about that for next year? These are all very important questions, right? There was a little bit of a budget flush for the fiscal year 2025 and orders, sorry, and funding coming out of NIH.

Strength in Biopharma year to date revenues was offset by weakness in <unk> Gov and software industrial research and semi markets. Finally year to date 2025 best revenues declined in the mid single digits percentage net of intercompany eliminations, the clinical MRI superconducting wire market in.

Speaker #3: All on a constant currency and year-over-year basis. Year-to-date 2025 BIOSPIN Group CER revenue of 612 million was shown, excuse me, was down mid-single digits percentage.

Proved in Q3 and is now flat year to date.

While our best research instruments business has been weaker due to a very strong prior year comparison.

Speaker #3: BIOSPIN saw growth in lab automation and services offset by a tough comparison with two gigahertz class NMR systems in Q3 '24 revenue versus non in Q3 of '25.

Okay.

So moving on to slide slide eight.

Frank Laukien: You all report that very well. It did improve in the third quarter, and particularly in September. I am aware of a cancer center that had fantastic NIH funding and cash coming in the door to where they even were. Flat or higher than the previous year. There was a mini budget flush. It went into a lot of multi-year grants. It went into things that they could fund readily. It went into a few instruments too. We sold some NMRs and some timsTOF and some other stuff. It wasn't very strong yet, which is why the strength in academic bookings for us in Q3 came from outside the US, but the US did improve a little bit sequentially. It just wasn't a growth driver yet year over year. That was that. NIH budget for 2026 and NSF budget, while we're at it.

You may have seen our press release that we had some recent NIH NSF funded orders for advanced <unk> instruments.

Speaker #3: BIOSPIN saw weakness in ACAGAV and biopharma revenues but improved order growth in both end markets in the third quarter of '25. Year-to-date 2025 CALEC Group revenue of 879 million increased in the low double digits percentage driven by microbiology and infection disease diagnostics, with strength in both the multibiotyper and the elliptic molecular diagnostics franchises.

Won't go through all of them, but here are several very unique enabling breakthrough to tools listed on this page with the respective customers that are really very important for our fundamental scientific research and very much very much. So also for drug discovery and disease.

<unk> research the aggregate value of these orders was disclosed previously it's about $10 million. It's expected. They are all expected to be installed and in revenue next year not in Q4.

Speaker #3: Life science mass spectrometry is seeing early traction for recently launched products, including the new TIMSS Omni and the new TIMSS Metabo, both launched at ASMS. Meanwhile, our molecular spectroscopy revenues remain stable, but we have strong applied markets orders in Q3 '25, as was mentioned earlier.

And maybe the.

The bigger message here is in that last bullet on slide eight that our scientific instruments <unk> orders as I mentioned earlier, we were pleased were all up mid teens percentage organically year over year in Q3, and this was despite lingering U S weakness.

Frank Laukien: We are not necessarily assuming that it's flat. We'd be delighted that it's flat. If we have to take 10% or 15% down, I think that will work for us too. I just want to be clear. It's hard to predict these things. We're not necessarily baking in an NIH budget flat. Again, delighted if it happens, but we can also work with it being down 10% or 15%. As you know, it's then actually more important whether the stuff actually gets disbursed regularly or gets held up for the majority of the year. We are, along with Q4 bookings, also looking forward to clarity on NIH, NSF, and DOE budgets for research for fiscal year 2026. Hopefully, that all comes in calendar Q4 to give us more visibility. China, yeah, some green shoots, yeah. They were less than $10 million in orders.

Speaker #3: Right, turn to slide seven now, please. Year-to-date 2025 BRUKER nano revenue of 775 million declined in the low single digits percentage. Revenues from advanced X-ray and nanoanalysis tools were down year over year partially offset by growth in spatial biology.

There have been some improvements in the U S. But primarily they are significant improvements outside of the U S Europe, Japan and China.

Right. Another press release, if you go to slide nine that we stressed it recently there are some new if you like applied markets. This is not food testing. This is security and defense and homeland security and in this case, we have a very very nice product line, that's sort of growing rapidly 30% year.

Speaker #3: Strength in biopharma year-to-date revenues was offset by weakness in ACAGAV and software industrial research and semi markets. Finally, year-to-date 2025 best revenues declined in the mid-single digits percentage net of intercompany eliminations.

Over a year and we were highlighting some recent orders.

For him explosive trace detector that you will find that a lot of European airports and an increasing number of those but also in south Korea and the middle East.

Speaker #3: The clinical MRI superconducting wire market improved in Q3 and is now flat year-to-date, while our best research instruments business has been weaker due to a very strong prior-year comparison.

Particularly performance and usability advantages this by the way isn't just an instrument sale versus than five or seven years of consumables and service sales. So it's a it's a nice steady business and we have been gaining market share and are pleased with those orders.

Frank Laukien: Clearly, well, in orders anyway, but clearly seemingly stimulus-related orders where customers said, yeah, this is stimulus money being released. Less than $10 million, not more. Again, I think that's a green shoot. We'll need to see how that continues in Q4. I think in Q2, there was none of that, so it's a little bit better, right? China contributed, but Japan and, quite honestly, Europe were really strong in ECOGOV orders in Q3. That's the color around the world. Okay, that's nice. Lastly, you just mentioned an order push-out. Can you quantify how large that was in the one you mentioned in your prepared comments? You mean, oh, revenue push-out? Yeah, there are a few sites that want delivery in Q1 rather than in Q4.

Speaker #3: So moving on to slide eight. You may have seen our press release that we had some recent NIH and NSF-funded orders for advanced NMR instruments.

And.

Cause of tensions in re re farming in Europe. We also got some significant defense detection orders from our central European Ministry of Defense.

Speaker #3: I won't go through all of them, but here are several very unique enabling and breakthrough tools listed on this page with the respective customers that are really very important for fundamental scientific research and very much so also for drug discovery, and disease biology research.

Not for Ukraine.

Others are worried as well and are obviously, because there isn't a smaller part of broker.

If you like as part of applied markets, that's growing very nicely, we thought we'd highlight that for you because obviously ACA golf was weaker this year.

Speaker #3: The aggregate value of these orders was disclosed previously. It's about $10 million. It's expected they're all expected to be installed and in revenue next year, not in Q4.

So.

To wrap up our third quarter P&L was still impacted by the various headwinds we've seen across the industry earlier. This year. However, the results came in ahead of our expectations are improved bookings in Q3, 25, and scientific instruments book to Bill ratio above 1.0 make us optimistic that we may be past the trough in demand.

Speaker #3: And maybe the bigger message here is in that last bullet on slide eight that our scientific instrument ACAGAV orders, as I mentioned earlier, we were pleased, were up mid-teens percentage organically year over year in Q3.

Frank Laukien: That also added to some of the more conservative guidance that we now have for the full year, but really implied for Q4 because that's all that's left. Okay, thanks. I think I mentioned a lot. It is true that, I mean, it's always true that we get more than half the orders in a quarter in the third month of every quarter. Yes, a lot of the orders and the order improvement really became clear in September. If all of these orders had come in in July, maybe some of them would have made it into Q4. Now, I mean, there's some small stuff. We'll go into Q4 and all this does, but most of the larger orders go into next year. Most of the larger orders that came in in September will be revenue in next year, I should be precise. Thank you. Thanks.

We look to build on this performance in Q4, and we are increasingly confident in fiscal year 2006 partial recovery.

Speaker #3: And this was despite lingering US weakness. It's been some improvements in the US, but primarily they're significant improvements outside of the US. Europe, Japan, and in China.

We expect significant improvements in our organic revenue performance compared to our meaningful decline organic decline in 'twenty five.

Speaker #3: Right. Another press release: if you go to slide nine, we stressed that yet recently. There are some new, if you like, applied markets. This is not food testing.

Importantly, we are taking up to $120 million in cost out of our business in fiscal year 2006 in order to drive significant margin expansion and strong double digit EPS growth.

Speaker #3: This is security and defense and homeland security. In this case, we have a very, very nice product line that's sort of growing rapidly, 30% year over year.

So in perspective, our transform project accelerate to that portfolio is fundamentally very strong and post genomic drug discovery and disease Biology research leveraging both proteomics and multi omics.

Speaker #3: And we were highlighting some recent orders from explosive trace detectors that you will find at a lot of European airports and increasing number of those, but also in South Korea and in the Middle East.

As well as spatial biology.

In innovative diagnostic solutions for microbiology, and molecular diagnostics and I'll also therapeutic drug monitoring and finally emerging really an emerging $100 million area for US is now the fast growth area of automated digitized our digital labs ready for <unk>.

Speaker #3: They have particularly performance and usability advantages. This, by the way, isn't just an instrument sale. This is then five or seven years of consumables.

Frank Laukien: The next question comes from Luke Sergott with ArcLeaf. Please go ahead. Great. Thanks for the questions. I just want to talk on China. I mean, coming in flat here, things kind of improved sequentially. Just talk about what you're seeing there more broadly. Pull forward. You talked a little bit about the stimulus, the murders row of key questions, but how are you guys thinking about Q4 and the exit rate? Ultimately, are we kind of seeing some type of stabilization here? Is this just kind of like a one-off? Well, good questions. I wouldn't read too much into, starting backwards, Luke, I wouldn't read too much into the Q4 2025 exit rate. That's just Q3 and Q4 relatively weak on the P&L, is pretty much the result of weak orders. Yes, and some new currency and tariff challenges early in the year.

Speaker #3: And service sales. So it's a nice steady business. And we have been gaining market share. And are pleased with those orders. And because of tensions and rearming in Europe, we also got some significant defense detection orders from a Central European Ministry of Defense.

AI or perhaps even driven by AI the automated AI labs. If you like these are four major profitable growth opportunities and they are complemented by our healthy diversification in industrial research Juicy market semiconductor metrology and as you've seen applied and security markets.

Speaker #3: This was not for Ukraine. But others are worried as well and are obviously there's a small part of BRUKER that if you like is part of applied markets that's growing very nicely.

Combining this outstanding portfolio with operational excellence and strong execution I am confident that by 2027, we can outgrow our markets again by two to 300 bps per year on average and continue our rapid margin expansion and double digit EPS growth after overcoming the mall.

Speaker #3: We thought we'd highlight that for you because obviously ACAGAV was weaker this year. So to wrap up, our third quarter P&L was still impacted by the various headwinds we've seen across the industry earlier this year.

Speaker #3: However, the results came in ahead of our expectations. Our improved bookings in Q3 '25 and scientific instruments book-to-bill ratio above 1.0 make us optimistic that we may be past the trough in demand.

<unk> Gov demand, new tariffs and strong currency headwinds in 2025 with a partial recovery in 2026.

Frank Laukien: We can work our way through those and offset them, and more than offset them by next year, but only partially this year. I wouldn't hesitate to take any given quarter this year as modeling something for next year. On China, yeah, China was a little bit better, right, sequentially. Not only in academic, not only some of the less than $10 million, I think it was closer to $6 million or something like that in stimulus green shoots. China felt a little better in Q3, perhaps all around, than in Q2 when they were probably staring down a trade war barrel. Maybe now, maybe that gets, that seems to have, even before the meeting that just happened recently, maybe the whole world's getting a little bit more optimistic that, well, we know the new tariff setup and there are not likely to be major trade wars.

Speaker #3: We look to build on this performance in Q4, and we are increasingly confident in a fiscal year '26 partial recovery. We expect significant improvements in our organic revenue performance compared to our meaningful decline organic decline in '25.

So with all of that let me turn the call over now to our CFO Gerald Herman who will review things in more detail Gerald thank.

Thank you Frank and thank you everyone for joining us today I'm pleased to provide some more detail on brokers third quarter and year to date 2025 financial performance starting on slide 11.

Speaker #3: Importantly, we are taking up to 120 million in cost out of our business in fiscal year '26 in order to drive significant margin expansion and strong double-digit EPS growth.

In the third quarter of 2025, our results came in.

In above our expectations on both the top and bottom lines in the.

Third quarter of 2005, <unk> reported revenue decreased <unk>, 5% to $865 million, which reflects an organic revenue decrease of four 5% year over year.

Speaker #3: So in perspective, our transformed project accelerate 2.0 portfolio is fundamentally very strong. In post-genomic drug discovery and disease biology research, leveraging both proteomics and multiomics, as well as spatial biology, in innovative diagnostic solutions for microbiology, molecular diagnostics, and now also therapeutic drug monitoring, and finally emerging really an emerging 100 million dollar area for us is now the fast growth area of automated digitized or digital labs ready for AI or perhaps even driven by AI.

Acquisitions contributed one 1% to <unk> topline foreign.

Foreign exchange was a $2 9% tailwind.

Geographically and on an year over year organic basis in the third quarter of 25 of our Americas revenue declined in the low single digit percentage European revenue was roughly flat, while Asia Pacific revenue declined in the mid single digit percentage, including flat performance in China.

Frank Laukien: Hard to say, right? China was a little better in Q3 than in Q2. All right. Thanks. I'll turn to the spatial and the demand that you guys are seeing there. Can you talk a little bit about the cadence for the instruments versus the consumables? Then the push here and ability to use your existing scale as this kind of hits the core to push further with academic, government customers, or deeper into pharma? Yeah. Good question. Yeah, spatial biology was all right. Slightly better orders or somewhat better orders than Q3, including international, I believe, as well. That's both consumables and instruments. Remember, some of the new workflows, like the whole transcriptome on the cosmics, of course, also will run on existing systems. They may need some upgrades, but you don't always need a new system for that.

EMEA region revenue declined by over 20%.

Scientific instruments organic revenue.

Speaker #3: The automated AI labs, if you like. These are four major profitable growth opportunities. And they are complemented by our healthy diversification in industrial research, QC markets, semiconductor metrology, and as you've seen, applied and security markets.

<unk>.

This segment declined five 4% in the third quarter of 25.

Mid single digit organic growth in <unk> was more than offset by a double digit organic decline in bio spin.

High single digit organic decline in broker nano.

Speaker #3: Combining this outstanding portfolio with operational excellence and strong execution, I am confident that by 2027, we can outgrow our markets again by two to three hundred bips per year on average.

BSI systems.

Revenue declined roughly 10%.

DSI aftermarket revenue increased mid single digit percentage.

Speaker #3: And continue our rapid margin expansion and double-digit EPS growth after overcoming the multiple ACAGAV demand new tariffs and strong currency headwinds in 2025 with a partial recovery in 2026.

Organically year over year.

As Frank mentioned earlier, our order bookings performance in the BSI segment was up organically in the mid single digit percentage year over year, and our BSI book to Bill ratio for the third quarter was above 1.0.

Frank Laukien: I think there was also strength in cosmics and celescape orders. Painscape is still very new, so a lot of that is sort of, well, we'll take a little while and have a number of labs that are going to have placements of the Painscape, do this new spatial genomics, and look at dysfunction in cancer and infectious disease before that turns into papers, before that turns into revenues. That's super interesting, but it's not going to be a big contributor yet, whereas Cosmics and Celescope are doing well, also including some of the consumables. Yeah, spatial biology is doing better. Of course, we could use more US academic funding. It was quite dependent. Well, two-thirds of that is academic government, and one-third is biopharma. That strengthening in biopharma also is good for spatial biology. As you know, so far in the US, that's stronger than the ECOGOV growth.

Speaker #3: So with all of that, let me turn the call over now to our CFO, Gerald Herman, who will review things in more detail. Gerald.

non-GAAP gross margin decreased 110 basis points to 51% Q3, 2025, non-GAAP operating margin was 12, 3%.

Speaker #2: Thank you, Frank. And thank you, everyone, for joining us today. Pleased to provide some more detail on BRUKER's third quarter and year-to-date 2025 financial performance.

Impacted by tariffs foreign exchange and the headwind from the prior year comparison, two gigahertz class <unk> and our third quarter two for revenue.

Speaker #2: Starting on slide 11. In the third quarter of 2025, our results came in above our expectations on both the top and bottom lines. In the third quarter of '25, BRUKER's reported revenue decreased 0.5% to $860.5 million.

On a non-GAAP basis Q3 dollars 25 diluted EPS was <unk> 45.

Down 25% from 60 since we posted in the third quarter 'twenty, four but improved sequentially and well ahead of our expectations.

Speaker #2: Which reflects an organic revenue decrease of four and a half percent year over year. Acquisitions contributed 1.1% to our top line, while foreign exchange was a 2.9% tailwind.

Our EPS in the third quarter of 25 includes <unk> <unk> dilution from the mandatory convertible preferred offering we completed in September and benefited from a lower non-GAAP effective tax rate of 24, 4%.

Speaker #2: Geographically, and on a year-over-year organic basis, in the third quarter of '25, our America's revenue declined in the low single-digit percentage. European revenue was roughly flat, while Asia-Pacific revenue declined in the mid-single-digit percentage.

On a GAAP basis, we reported diluted loss per share of <unk> 41.

Reflecting non cash goodwill and intangibles impairment charges of $119 4 million in restructuring charges in the third quarter of $34 5 million.

Speaker #2: Including flat performance in China. For our IMEA region, revenue declined by over 20%. Scientific instruments organic revenue grew segment declined 5.4% in the third quarter of '25, as mid-single-digit organic growth in CALID was more than offset by a double-digit organic decline in biospin and a high single-digit organic decline in BRUKER nano.

Frank Laukien: Yeah, great, thanks. The next question comes from Subbu Nambi with Guggenheim. Please go ahead. Hey, thank you for taking my question, Frank. Some of the niche end markets in 2026, like diagnostics and maybe semis, what do those look like next year? Can any tech be a low double-digit grower in your mind? Yeah, I mean, diagnostics is very important for us, right? It's all about $500 million. They've done well in 2025, both in clinical microbiology and the molecular diagnostics that are both in that infectious disease division. MALDI Biotyper, good growth, very good growth in consumables and software and so on. Now in that business, I think it's 60% aftermarket, which is service, consumables, but also database subscriptions. Very healthy there. The diagnostics business, the ELITech business primarily, is a delight this year. It's growing nicely. It's expanding this year, 2025, so it's growing its margins.

non-GAAP weighted average diluted shares outstanding in the third quarter of 2025 or $152 million flat compared to the third quarter of 2024.

Slide 12 shows brokers performance on a year to date basis for 2025, which is similar drivers to those in the third quarter.

Turning now to slide 13 in the first nine months of 2025, we had operating cash outflow of $95 $7 million driven by lower profitability timing of tax and key vendor payments and restructuring expenses.

Speaker #2: BSI systems revenue declined roughly 10%, while BSI aftermarket revenue increased mid-single-digit percentage organic year over year. As Frank mentioned earlier, our order bookings performance in the BSI segment was up organically in the mid-single-digit percentage year over year.

We would expect to see improved cash flow in the fourth quarter, our largest and most profitable quarter of the year.

Speaker #2: And our BSI book-to-bill ratio for the third quarter was above 1.0. Non-GAAP gross margin decreased 110 basis points to 50.1% Q3 2025. Non-GAAP operating margin was 12.3%, impacted by tariffs, foreign exchange, and the headwind from the prior year comparison of two gigahertz class NMRs in our third quarter '24 revenue.

Our strongest cash flow quarter.

Turning now to slide 15.

We're upping, our full year 2020 forecast and outlook.

To reflect Q3 results order timing and the impact of our September.

The mandatory convertible preferred offering our outlook for the full year of 2025 now assumes revenue in the range of $3 four 1% to $3 44 billion.

Frank Laukien: It's growing, which is nice this year. It's actually at, I don't know the exact growth rate, it's growing somewhere in the single digits, maybe even high single digits, which is lovely. Its placements have really outperformed significantly. I know you can't take placements to the bank, but next year you will be. They had a lot of placements of their Ingenius and BGenius stations. The commercial synergies with Bruker are really working, and they're getting into countries and into labs they previously couldn't get. I think their placements are something like 20% or more ahead of their business plan, which isn't revenue this year. When these systems are placement under reagent rentals, then it takes six months until you really have the revenue ramp, but hopefully, then you have five to seven years of really solid revenue and consumables pull through. That's going really well.

Speaker #2: On a non-GAAP basis, Q3 '25 diluted EPS was $0.45, down 25% from the $0.60 we posted in the third quarter of '24, but improved sequentially and was well ahead of our expectations.

Reflecting an organic revenue decline of 4% to 5%.

Late order bookings in the third quarter as well as certain customer site readiness issues are expected to push a portion of revenue. We previously expected in the fourth quarter into fiscal year 2026.

Speaker #2: Our EPS in the third quarter of '25 includes a one-cent dilution from the mandatory convertible preferred offering we completed in September, and benefited from a rate of 24.4%.

For full year 'twenty five revenue growth contribution from acquisitions is expected to be approximately three 5% and we expect a foreign currency tailwind of about two 5%.

Speaker #2: On a GAAP basis, we reported diluted loss per share of 41 cents, reflecting non-cash goodwill and intangibles impairment charges of 119.4 million dollars, and restructuring charges in the third quarter of 34.5 million dollars.

This leads to updated reported revenue growth guidance of 1% to 2%.

For operating margins in 2025, we now expect approximately 250 basis point decline in operating margins year over year.

Speaker #2: Non-GAAP weighted average diluted shares outstanding in the third quarter of 2025 were 152 million, flat compared to the third quarter of 2024. Slide 12 shows BRUKER's performance on a year-to-date basis for lower non-GAAP effective tax 2025, which has similar drivers to those in the third quarter.

This consistent headwinds of 60 basis points from M&A 60 basis points from tariffs 65 basis points from foreign exchange as well as a 65 basis point decline in organic operating margin.

Frank Laukien: Semi, you have to look at it on an annual basis. I think we had, this year, two quarters of fantastic orders and two quarters of not-so-fantastic orders. Over the year, it's all right. I think it's flattish this year. I don't think there's anything structural there. Revenue-wise, it's been a little weaker, and we expect that to improve next year. Semi really has to look at it on an annual level. It's a very nice margin contributor. Semi now is approaching or is around $300 million in annual revenue. It's also pretty meaningful for us and has very, along with the diagnostics business, has some of the best incremental margins. Those are very core to us. These are not niches for us, even though we love the post-genomic era. Both of those are just really important core businesses. Thank you for that, Frank.

On the bottom line our updated full year 2025 guide now reflects non-GAAP EPS in a range of 185 to 190.

Speaker #2: Turning now to slide 13, in the first nine months of 2025, we had an operating cash outflow of $95.7 million, driven by lower profitability, timing of tax payments, key vendor payments, and restructuring expenses.

This includes seven dilution from our mandatory convertible preferred offering we completed in September.

For your modeling, we expect the MCP offering to have a roughly <unk> 20 dilutive impact on our fiscal year 2026 Etfs.

Speaker #2: We expect to see improved cash flow in the fourth quarter, our largest and most profitable quarter of the year, and always our strongest cash flow quarter.

Despite this dilution we continue to expect double digit non-GAAP EPS growth in fiscal year 'twenty six due to the significant cost savings initiatives. We are implementing this year.

Speaker #2: Turning now to slide 15, we are updating our full-year 2025 forecast and outlook to reflect Q3 results, order timing, and the impact of our September mandatory convertible preferred offering.

Other guidance assumptions are listed on the slide our full year 2025 ranges have been updated for foreign currency rates as of September 32025.

Speaker #2: Our outlook for the full year of 2025 now assumes revenue in a range of 3.41 to 3.44 billion dollars, reflecting an organic revenue decline of four to five percent.

Frank Laukien: Just to follow up, can you unpack where you saw orders incrementally positive from a product perspective? Is it the lower-priced equipment? How have consumables been impacted? Any color you could share there? For diagnostics, for molecular diagnostics and the ELITech, remember they're primarily active in Europe, in selected countries in Asia, not in China, for instance, in parts of Africa, parts of Latin America. The strength there has been particularly in Europe, the placement strength that I mentioned. Can you repeat the question, Subbu? I'm sorry. I thought you were referring to diagnostics, but yes. My first question was diagnostics. Yeah. Sorry. Backing up. In general, the order strength that you saw this quarter, where did you see the strength coming from from a product perspective, either diagnostics or outside of diagnostics?

With respect to the fourth quarter of 2005, we still expect relatively soft organic revenue performance with a mid to high single digit percentage decline year over year due to lingering effects of weaker orders earlier in the year.

Speaker #2: Late order bookings in the third quarter as well as certain customer site readiness issues are expected to push a portion of revenue we previously expected in the fourth quarter into fiscal year 2026.

We expect non-GAAP EPS for the fourth quarter to show significant sequential improvement, but still be down meaningfully year over year in.

Speaker #2: The full year '25 revenue growth contribution from acquisitions is expected to be approximately 3.5%, and we expect a foreign currency tailwind of about two and a half percent.

Implied by our guidance.

To wrap up.

First half 2025 market headwinds adversely impacted our financial performance in the full year of 2025. However, we are encouraged by our solid order performance in the third quarter of 25 and expect to drive improved P&L performance.

Speaker #2: This leads to updated reported revenue growth guidance of one to two percent. For operating margins in 2025, we now expect approximately 250 basis points decline in operating margins year over year.

Full year 2006 and beyond.

With our cost savings plan is well on track we are fully committed to significant margin expansion and double digit EPS growth in fiscal year 2006.

Speaker #2: This consists of headwinds of 60 basis points from M&A, 60 basis points from tariffs, 65 basis points from foreign exchange, as well as a 65 basis point decline in organic operating margin.

With that I'd like to turn the call back over to Joe Thanks very much.

Thanks, Gerald we will now begin the Q&A portion of the call as a reminder to allow everyone time for questions. We ask that you limit yourself to one question and one follow up operator.

Speaker #2: On the bottom line, our updated full year 2025 guide now reflects non-GAAP EPS in a range of 185 to 190. This includes seven cent dilution from our mandatory convertible preferred offering we completed in September.

Frank Laukien: I think, Subbu and Gerald, I'd say the orders strength in the third quarter was coming from larger ASP-based instruments. We did have some volume, particularly coming out of our optics and AXS businesses, which tend to have lower ASPs, but I'd say the bulk of the performance in the orders was particularly coming out of the European markets as well, just to clarify that. We saw considerable strength in the European markets, both in the ECOGOV side, particularly. I think I can answer it now. It took me a second. The strength in orders in Q3 of 2025 had very little to do with diagnostics. Diagnostics was just coming along, and it's fine. The more discrete items were strength in ECOGOV outside of the US, biopharma, and applied. That's right. None of those include diagnostics. Thank you for that. Sure. The next question comes from Casey Woodring with JPMorgan.

We will now begin the question and answer session to ask a question you May Press Star then one on your Touchtone phone.

If youre using a speakerphone, please pick up the handset before pressing the keys.

Speaker #2: For your modeling, we expect the MCP offering to have a roughly $0.20 diluted impact on our fiscal year 2026 EPS. Despite this dilution, we continue to expect double-digit non-GAAP EPS growth in fiscal year '26 due to the significant cost savings initiatives we're implementing this year.

If at any time. Your question has been addressed and you would like to withdraw your question. Please press Star and then two.

Our first question comes from Amit <unk>.

With.

<unk> Leerink partners. Please go ahead.

Yeah, Hi, Frank Thanks for taking my questions here.

First one on the book to Bill good to see more than one and congrats on the quarter.

Speaker #2: Other guidance assumptions are listed on the slide. Our full year 2025 ranges have been updated for foreign currency rates as of September 30th, 2025.

Just given the order momentum youre seeing here, but.

I'm just wondering how has that trended in the fourth quarter are you continuing to see the mid teens organic order growth here.

Speaker #2: With respect to the fourth quarter of '25, we still expect relatively soft organic revenue performance with a mid to high single-digit percentage decline year over year due to lingering effects of weaker orders earlier in the year.

And maybe could you elaborate a bit just a number of moving parts here.

How is the international momentum continued as it more I could go versus pharma and maybe tell us a bit more on the academic side.

Speaker #2: We expect non-GAAP EPS for the fourth quarter to show significant sequential improvement, but still be down meaningfully year over year. As implied by our guidance.

Aside of the U S are you starting to see some.

Frank Laukien: Please go ahead. Great. Thank you for taking my questions. On orders, historically, orders improve sequentially in Q4 in your business, but you've talked here today about some catch-up in academic and government in Q3. Can you just maybe walk through what the range of outcomes looks like in Q4 from an order exit rate perspective? How safe is it to assume orders step up sequentially, or are there scenarios where orders could be flat or down in Q4? I have a follow-up. Thanks. Sure, Casey. In ECOGOV, where we observed a little bit of catch-up was in the US. I don't think that there wasn't any holdback. Well, actually, in the US and in China, a little bit. In the rest of the world, I think that catch-up, I'm not aware of that. China and the US and ECOGOV have been holding back.

Some recovery there.

Speaker #2: To wrap up, the first half of 2025 market headwinds adversely impacted our financial performance in the full year 2025. However, we're encouraged by our solid order performance in the third quarter of '25 and expect to drive improved P&L performance in the full year '26 and beyond.

Given the points you mentioned DNP and couple of other points you mentioned in the slides.

Yes, thank you very much so.

We really don't have Q4 data yet it's too early.

So.

I just can't comment on Q4.

Speaker #2: With our cost savings plans well on track, we're fully committed to significant margin expansion and double-digit EPS growth in fiscal year '26. With that, I'd like to turn the call back over to Joe.

No meaningful data available yet.

Moving parts <unk> Gov.

The strength in.

Gov orders was <unk>.

Primarily outside of the United States.

Speaker #2: Thanks very much. Thanks, Gerald. We will now begin the Q&A portion of the call. As a reminder, to allow everyone time for questions, we ask that you limit yourself to one question and one follow-up.

But the United States were less week, alright, less soft is that a word anyway. So Q3 was better in the United States for <unk> orders than Q2, and we saw some orders come through I gave you. Some MMR examples but of course. It was it was it was broader than that also included Gamestop in micros.

Speaker #2: Operator?

Speaker #3: We We will now begin question and answer session. You ask a question, you may press star, then one on your touchstone phone. If you're using a speakerphone, please pick up the handset before pressing the keys.

Scopes and other stuff.

There.

Frank Laukien: That's why Q2 orders, for instance, in both of those geographies were weak. To your second part of your question, Q4 is always strong. The question for Q4 will not be, will it be up sequentially over Q3? That's pretty much a given, but whether what the trend will be year over year compared to Q4 of last year. Got it. That's helpful. Yeah, no, no, that definitely helps. My second one, just quickly on backlog, I think last quarter you noted you had six and a half months, and you talked about that going down to five months in a normalized environment. Maybe just walk through kind of how you're seeing that play out over the course of 2026. Thank you. Well, what I can, this is Gerald.

Hard to say, what's the trend in the U S. Because they are clearly in the us that was a little bit of catch up in Q3 compared to Q2, and maybe even Q1 in <unk>.

Speaker #3: If at any time your question has been addressed and you would like to withdraw your question, please press star and then two. Our first question comes from Paneet Sada with Leerink Partners.

<unk> Gov Org.

<unk> in Europe and Japan.

Speaker #3: Please go ahead.

Speaker #4: Yeah, hi, Frank. Thanks for taking my questions here. First one on the book-to-bill: good to see more than one, and congrats on the quarter.

Little bit in China also thats why they might be green shoots we are quite encouraging and that's why our <unk> orders.

Year over year were up considerably in Q3 don't <unk> don't think that we're now in a high teens growth trend all of a sudden that's just a quarter in Q through 324 was not the strongest but anyway. It was it was.

Speaker #4: Just given the order momentum you're seeing here, but just wondering, how has that trended in fourth quarter? Are you continuing to see the mid-teens organic order growth here?

It was very encouraging and we hope that will continue in Q4, but I wouldn't and yes, the activity and the opportunities are great and are encouraging, but I wouldn't read anything into that yet just too early to comment on Q4, we do need Q4 to then get more meaningful growth and margin.

Speaker #4: And maybe could you elaborate a bit just a number of moving parts here? How has the international momentum continued? Is it more I could go versus pharma?

Speaker #4: And maybe tell us a bit more on the academic side of the US. Are you starting to see some recovery there? Given the points you mentioned, DNP and a couple of other points you mentioned in the slide.

Frank Laukien: What I can comment on is that we currently have about seven months of backlog through the third quarter of 2025, which is actually up now from the six and a half months we quoted at the end of the second quarter. I mean, I guess to a large extent, it really depends on our 2026 performance. It's really going to depend on how it looks like for the fourth quarter in terms of our revenue performance. Based on our guide, it looks like we will still carry considerable backlog into the 2026 period. Right. All right. Great. Thank you. You're welcome. Thank you. The next question comes from Brandon Collard with Wells Fargo. Please go ahead. Hey, Gerald. Thanks for taking the question. Just a couple of housekeeping items. You give us an updated interest expense number for the year. What's the run rate for the fourth quarter?

Numbers for 2026, we're not going to do that today, we're not able to do that today until we really see how Q4 comes in particular the orders obviously.

Speaker #4: Yes. Thank you very much, Paneet. So we really don't have Q4 data yet. It's too early. So I just can't comment on Q4. There's no meaningful data available yet.

To your to the other moving pieces Puneet, yes, biopharma has been.

Reasonable.

In our case that great, but okay in the first half of the year much better than the third half of the year in terms of orders.

Speaker #4: Moving parts, I could go. The strength in I could go orders was primarily outside of the United States, but the United States were less weak.

Particular strength there in the U S. But also outside of the U S backlog.

<unk>, particularly sorry, biopharma, particularly in the U S and the applied market strength, which is a good sign of macroeconomic trends that was pretty that had a pretty broad.

Speaker #4: All right, less soft. Is that a word? Anyway, so Q3 was better in the United States for iCorder orders than Q2, and we saw some orders come through.

International distribution I don't know that I would you highlight any geography there so.

Speaker #4: I gave you some NMR examples, but of course, it was broader than that. It also included Tim Stoff and microscopes and other stuff. They're hard to say what the trend in the U.S. is because they're clearly in the U.S.

So that may add some color to the admittedly.

Multiple moving pieces and the effect that broker that prior order weakness now shows up in the P&L, whereas.

Frank Laukien: Is that a good figure to assume for 2026? Is the impact of the share count from the MCP offering about 13 million shares? Thanks. Yeah. To answer your last question first, the answer is yes, roughly. The first part, we'll go through, Brandon, a little more modeling on the interest because it gets a little complicated, partly because you may know we had some gains, some foreign exchange gains that get covered in that line as well. Somewhere in that range, if you're quoting, our interest is correct. We'll talk more about that in our modeling discussions. The next question comes from Josh Waldman with Cleveland Research. Please go ahead. Hey. For you. First, I wondered if you could talk a bit more about what you're seeing in Europe. Was it primarily ECOGOV accounts that improved there, or did you also see pharma and applied accounts improve as well?

Speaker #4: There was a little bit of catch-up in Q3 compared to Q2 and maybe even Q1. In I could go, orders in Europe and Japan and a little bit in China also.

The new order.

Improvements encouragement and maybe maybe this momentum into Q4 goes well and it is more likely to show it will show up all in 2026.

That helps.

Speaker #4: That's why they might be clean shoots were quite encouraging, and that's why our I could go orders year over year were up considerably in Q3.

Got it that's very helpful and anything on the ultra high frequency.

And in March how are you thinking about those obviously tougher comp in the third quarter, but as we go into 'twenty six.

Speaker #4: Don't think that we're now in a high-teens growth trend all of a sudden. That's just one quarter in Q3 '24; it was not the strongest, but anyway, it was very encouraging.

How does the momentum there and we have been waiting for us to acquire more of those.

Instruments.

Thank you <unk>.

As the Enigma there, but obviously there is also other geographies and I still can't call. The U S trends, obviously nothing has come through so far so so we'll see we're expecting at least one <unk>.

Speaker #4: And we hope that we'll continue in Q4, but I wouldn't—and yeah, the activity and opportunities are great and are encouraging. But I wouldn't read anything into that yet, just too early to comment on Q4.

<unk> for the gigahertz class in.

Speaker #4: We do need Q4 to then give more meaningful growth and margin numbers for 2026. We're not going to do that today. We're not able to do that today until we really see how Q4 comes in, particularly the orders, obviously.

Q4, not in the U S.

And there's a number of cases.

Brewing around the world and including in the U S.

Frank Laukien: At this point, what's your confidence level on the sustainability in stronger orders? I mean, were there any one-off funding programs or anything like that that released in the third quarter that leave you, I guess, nervous about the durability of stronger orders there? Yeah. I'd say, generally speaking, Europe was stronger. We did see strength in both ECOGOV as well as applied and biopharma. Those are good signs. I don't think there were specific one-offs related to those trends. I think we're more confident, but I would say we need to see, as Frank has repeated a couple of times here, we need to see the fourth quarter order performance in order to confirm that specifically. All of those markets, in particular on the ECOGOV side, European, were not being driven by one-off improvements or orders. Got it. Okay. A follow-up.

Today's too early to do that so when we gave guidance for 2006 and.

Speaker #4: To the other moving pieces, Paneet, yes, biopharma has been reasonable in our cave—not great, but okay—in the first half of the year, and much better in the third half of the year in terms of orders.

Presumably in early February of 2006, we can also comment on.

What has what has come in where we have clear line of sight for ultra high field for the gigahertz class. So yes, nothing in revenue in Q3.

Speaker #4: Particular strength there in the US, but also outside of the US, but I could go particular—sorry, biopharma particularly in the US. And the applied market strength, which is a good sign of macroeconomic trends, that was pretty—that had a pretty broad international distribution.

We expect hopefully one order in Q4.

These things get delayed by a quarter anyway, its just not such a big part of our business anymore, I know theyre easier to count and indeed in Q3, a lot of our organic decline had to do with these two.

Speaker #4: I don't know that I would highlight any geography there. So that may add some color to the admittedly multiple moving pieces. And the effect of Brooker that prior order weakness now shows up in the P&L, whereas the new order improvements and encouragement and maybe it is momentum if Q4 goes well, it's more likely to show—will show up all in 2026.

Gigahertz class systems in Q.

Q3, 2004 revenue, which accounted for more than $25 million of our revenue and comes with nice operating profit and margins. So it isn't that did have an effect on Q3 and anyway thats. The color I can give you more more to come when we give guidance in early February.

Frank Laukien: I wondered if you could provide more color on what you're seeing out of pharma. I mean, it sounds like you saw sequential improvement in bookings. I forget if you commented what orders look like year over year. Does it seem like accounts are trying to push orders through by year-end, or does this seem like maybe a change in how they're viewing medium-term investment in research tools? Good questions. Josh, this is Frank. Not aware of any particular drives to get orders in placed before the end of the calendar year. I would take this as biopharma having invested less now. There was kind of a COVID or immediate post-COVID boom. Well, then there was a hangover, right? Then some concerns about most favored nations' pricing and how much CapEx did they need to move things in production to the US.

Got it thank you.

And the next question comes from Michael <unk> with Bank of America. Please go ahead.

Speaker #4: Hope that helps.

Speaker #1: Got it. That's very helpful. And anything on the ultra-high frequency gigahertz NMRs? How are you thinking about those? Obviously, the tougher comp in the third quarter, but as you go into 2026, how is the momentum there?

Michael Your line may be on mute.

Speaker #1: I know we've been waiting for US to acquire more of those instruments. Thank you.

Speaker #2: Yeah, the US is the enigma there, but obviously, there's also other geographies. And I still can't call the US trends. Obviously, nothing has come through so far.

Hi, This is Mike on for this event has gone for Mike could you give us that.

Speaker #2: So we'll see. We're expecting at least one order for the gigahertz class in Q4, not in the US. And there's a number of cases brewing around the world and including in the US, but today's too early to do that.

The impact of the government shutdown that youre seeing in four Q and is that baked into the updated outlook. Thank you.

Well Luke.

That's a good question and it's not formally baked into our outlook. So far we have assumed that the effect will be relatively.

Minor, but indeed.

If this were to continue for a full second month or so then this may delay some new brands. Some orders it could also delay some installations.

Speaker #2: So, when we give guidance for '26, presumably in early February of '26, we can also comment on what has come in or where we have clear line of sight for ultra-high field or for the gigahertz class.

Frank Laukien: Many of them have now committed to do that. It doesn't happen overnight. Maybe that has cleared the decks a little bit to where they are investing in tools that will make drug discovery more efficient and give them better insights. Those tools, that's exactly what we provide you. Yes, you need sequencers, but you need a hell of a lot more than that to really have deeper disease biology and then drug target, drug mechanism of action insights. Hopefully, the still very poor yield and enormous expense and length of bringing a successful drug to market will improve. That requires they are the biggest integrated fans of this hypothesis or thesis or fact, I would say, that we are in the post-genomic era and we need to understand the disease biology and the drug mechanisms a lot better to get less attrition and more yield and better drug discovery.

So far we have become aware of anything that's gets released.

Speaker #2: So yes, nothing in revenue in Q3. We expect hopefully one order in Q4. Sometimes these things get delayed by a quarter. Anyway, it's just not such a big part of our business anymore.

We said, we think that our Q4 guidance is now appropriately conservative to absorb some of that and maybe what we've seen so far but no. If there was a further multi week or multi month shutdown.

Speaker #2: I know they're easier to count. And indeed, in Q3, a lot of our organic decline had to do with these two gigahertz class systems in Q3 '24 revenue, which accounted for more than 25 million of our revenue, and comes with nice operating profits and margins.

That could have additional impacts that are not presently in our guidance.

Understood. Thank you and then I know that you're not formally guiding on 2026 today.

You called out meaningful improvement versus the minus 4% to 5% organic and 25.

Speaker #2: So we did have an effect on Q3. And anyway, that's the color I can give you. More to come when we give guidance in early February.

Is it fair to assume that you can grow revenues in 2020 or.

Speaker #1: Got it. Thank you.

Are we looking at flat year over year. Thank you.

Speaker #5: And the next question comes from Michael Ryskin with Bank of America. Please go ahead. Michael, your line may be on mute.

Frank Laukien: They completely agree with that. They may not use the same terminology, but that's how they're investing. I would just add that the third-quarter performance on revenue was good, okay? The order performance from biopharma across the globe was strong in the third quarter from an order perspective. Got it. Thanks, guys. The next question comes from Doug Schenkel with WUF Research. Please go ahead. Hey, good morning, guys. Thanks for fitting me in. Gerald, how do we balance what you've talked about in terms of the cost savings initiatives? You sound as good as ever on those. You've exhibited some confidence about what you can do in 2026 from a margin expansion standpoint, seemingly in any growth environment. I mean, at one point, I think last quarter, you talked about getting 300 basis points of margin expansion next year, even in a flat growth environment.

We're not making that assumption, yes, a fair question of course.

We really do want to see our Q4 dollars 25 bookings in.

In order then to give.

Hopefully reliable guidance in February of 2006.

So yes, I mean this this year this year 25 were coming down organically quite a bit right.

Speaker #6: Hi. This is Mike on for—this event has gone for Mike. Could you give us the impact of the government shutdown that you're seeing in Q4?

We.

Undoubtedly can do much better than that next year, but were not presently.

I don't want to state any assumptions because then you will take them as guidance then they're not but.

Speaker #6: And is that baked into the updated outlook? Thank you.

But we just want to make sure that with a significant cost cutting that we're doing.

Speaker #4: Well, that's a good question. And it's not formally baked into our outlook. So far, we have assumed that the effect will be relatively minor. But indeed, if this were to continue for a full second month or so, then this may delay some new grants, some orders; it could also delay some installations.

Even without growth.

Which is an assumption, but even without growth we can expand our operating profit margins very significantly paying out $250 to 300 bps or something like that and yes. We expect we continue to expect double digit EPS growth.

Even after absorbing the roughly 20% dilution that Gerald mentioned during his prepared remarks for the additional.

Speaker #4: So far, we haven't become aware of anything that gets—we think that our Q4 guidance is now appropriately conservative to absorb some of that and maybe what we've seen so far.

Dilution from the mandatory converts that we did in September so we still expect to do double digit non-GAAP EPS growth next year.

Frank Laukien: On the other hand, I think you increased your assumption for organic operating margin headwinds by 45 basis points for the year, which is pretty material with one quarter to go. I'm just trying to figure out how do we balance these things? Is there some risk that the benefits that you expect to occur over time are going to take a little bit longer to show up in the P&L just because of maybe the environment we're in and the fact that I think a lot of these changes that you're making are being done outside the US, where regulations can work against you? Again, I'm just trying to think about this as we try to set you guys up to succeed with realistic targets for 2026. Thank you. Yeah, sure. Nice to hear from you, Doug. Here's what I'd say.

Speaker #4: But no, if there was a further multi-week or multi-month shutdown, that could have additional impacts that are not presently in our guidance.

And that's without that simply for mathematically that simply.

But this is without growth without growth is not our preliminary guidance.

There is.

That's what we're looking at right now we cannot with preliminary guidance for US right now on growth does not make sense until we have seen our Q4 orders for broker that's going to be very important for next year.

Understood. Thank you for the color.

Thank you.

And the next question comes from Tycho Peterson with Jefferies. Please go ahead.

Hey, Thanks, Brad I want to pick up on that margin point. So it sounds like you are committing to the 300 basis points of margin expansion, even if top line flat I guess.

Frank Laukien: First, our cost-saving initiatives will be, and we expect them to be, at the high end of the range we quoted, this $100 to 120 million for fiscal year 2026, and we're fully committed to that. Actually, we're well on track with that. Ninety-five percent of the actions that needed to be taken to realize that are already underway or have been fully implemented, so very confident with respect to that. I think, more generally, our expectation around margin expansion of closer to 300 is where we are, even under relatively weaker revenue conditions for 2026. That's the position we've taken, and I think we're holding to that. I think the issue for us, as you already know, I think, Doug, is some of these activities around cost savings do take a bit of time just because we have to go through a process, particularly in Europe.

Given that you are running at the high end of the $100 million to $120 million cost savings target in the near term should we interpret the upper end of savings is simply kind of increasing confidence in hitting that margin target next year or the easy capacity do better.

Okay. So.

Nice question Tycho.

<unk>.

I wasn't confirming a number.

I know you've mentioned one.

Not saying take that number out of your model, but I'm not confirming it either.

We are I think the second part of your question I think it's fair to say, we hope to have increased confidence in in getting to very significant margin expansion and double digit EPS growth all in <unk>.

Including the MCP and that's exactly why we're driving towards the high end of our cost cutting targets, so you're spot on with that one.

Frank Laukien: A lot of our cost-saving actions are driven around Europe because of our footprint, so there's going to be a slight likely delay in some of this as we see more of it hitting in the second quarter of 2026 as opposed to in the first. That doesn't take us off the target, I think. Let me also—I mean, we did get Europe, there are other economic problems and layoffs by other companies. We got very good cooperation, for instance, in Germany and France, which can be difficult from our workers' councils and committee d'entreprise. They've agreed. They've approved that what we're doing is reasonable and protects the core and all of that. Good cooperation. When Gerald said that, yeah, Q1 will have—the $120 million for the year, we're very committed to that. Q1 will have, I don't know, 90% or 95% of the run rate cost savings implemented.

Okay, and then just following a little bit on your assumptions, we're not talking numbers for 'twenty six but just the outlook there assuming flattish NIH budget I mean, just talk a little bit about some of the gives and takes around multi year grants.

I assume youre not expecting any budget flush here in the near term, but then as we think about next year do you think LNG orders.

We will grow and then can you flesh out your comments on China stimulus how material was that and how do you think about that for next year.

Yes. These are all very important questions right. So so there was a little bit of a budget flush for the fiscal year 'twenty five and orders sorry.

<unk>.

Funding coming out of NIH, you all report that very well.

It did improve in the third quarter and particularly in September I'm aware of a cancer center that had fantastic NIH funding and cash coming in the door towards even were flat or higher than the previous year. So there was a mini budget flush we went into a lot of multiyear grants that went into.

Frank Laukien: A few things, just the way they're timed, will come in in Q2. It's not going to be a big modeling difference, Doug, or anybody else. Yes, that's how it flows. The $120 million is not some sort of a Q4 run rate. That's for the full year. Exactly. Just to your earlier part of your question, I mean, we did have—with respect to the fourth quarter of 2025, we do have some mixed challenges in the fourth quarter for 2025 that we didn't see in the previous year as well. I think you're going to see some—you did see a change in the overall guide from an organic. Operating margin impact with respect to the fourth quarter. That's the explanation for that, Doug. Okay. I'll leave it there. Thank you, guys. Thank you. Thank you all. This concludes our question-and-answer session.

Things that they could fund readily it went into a few instruments to we sold some <unk> and some Tim soften some other stuff it wasn't very strong yet which is why the strength in academic bookings in for US in Q3 came from outside the U S. But the U S did improve a little bit sequentially. It just wasn't.

As a growth driver yet year over year.

So that was that NIH budget for 2006, and NSF budget, while we're at it.

We are not necessarily assuming that it's flat we'd be delighted that it's flat.

And as we have to take 10% or 15% down and I think that will not that.

That will work for us too I just wanted to be.

It is hard to predict these things these days.

So we're not necessarily baking in an NIH budget flat again delighted if it happens, but we can also work with it being down 10% or 15% as you know it's been actually more important whether this stuff actually gets dispersed regularly or gets held up for the majority of the year, but we are.

Frank Laukien: I would like to turn the conference back over to Joe Kosta for any closing remarks. Thank you for joining us today. Bruker's leadership team looks forward to meeting with you at an event or speaking with you directly during the fourth quarter. Feel free to reach out to me to arrange any follow-up. Have a good day. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Along with Q4 bookings were also looking forward to clarity on NIH NSF and Dod budgets for research for Nick for fiscal year 2006, hopefully that all comes in in calendar Q4 to give us more visibility.

China, Yes, some green shoots yes, so they were less than $10 million in.

<unk>.

Clearly while in orders anyway, but it clearly is.

The stimulus.

Related orders, where a customer said gathers the stimulus money being released so less than $10 million.

And.

Again, I think that's a green shoot.

And growth need to again see how that continues in Q4, but I think in Q2, there was none of that so it's a little bit better right. So.

China contributed but Japan and quite honestly Europe, we're really strong in <unk> Gov orders in Q3.

That's the color around the world.

Okay. Thanks, and then lastly, you just mentioned in order push out can you quantify how large that was the one you mentioned in your prepared comments.

Oh, you mean.

Revenue push out yes.

Funding coming out of NIH. You you all report that very well um did improve in in, in the third quarter. And particularly in September, I'm aware of a Cancer Center that had fantastic, NIH funding and, and cash coming in the door to where they even were flat or or higher than the previous year. So there was a mini budget slushy, it went into a lot of multi-year Grants, it went into things that they could fund readily. It went into a few instruments too. You know, we sold some nmrs and some tips off and some other stuff. It wasn't very strong yet, which is why the strength in academic, bookings, in for us in Q3 came from outside the US, but I, but I, but the US did improve a little bit sequentially. It just wasn't a growth driver yet year over year.

There is a few sites that.

Have that one delivery in Q1, rather than in Q4. So that also added to some of the more conservative guidance that we now have four for the full year, but really implied for Q4, because thats all thats left.

So that was that NIH budget, uh, for 26 and NSF budget while we're added. Um, we are not necessarily assuming that it's flat. We'd be delighted that it's flat.

Okay.

You know, if we have to take 10 or 15% down, I think that will work for us too. I just want to be.

And I think I mentioned I think I mentioned it is true that I mean, it's always true that we get more than half the orders in a quarter in the third month of every quarter, but yes, a lot of the orders and the order improvement.

It became clear in September.

So.

If all of these orders have come in in July and maybe some of them would have made it into Q4.

Now there is I mean, there's some small stuff will go into Q4 and all of this does but most of the large orders go into next year. Most of the larger orders that came in in September will be revenue in next year actually to be precise.

Thank you.

Thanks.

It's hard to predict these things these days. Um, so we're not necessarily baking in an NIH budget. Flat again, delighted if it happens, but we can also work with it being down 10 or 15%. As you know, it's then actually more important whether the stuff actually gets dispersed regularly or gets held up for the majority of the year. But we are, along with Q4 bookings, also looking forward to clarity on NIH, NSF, and DOE budgets for research for the next fiscal year 2026. Hopefully, that all comes in in calendar Q4 to give us more visibility.

The next question comes from Luke.

China. Yeah, some green shoots. Yeah, so they were less than 10 million in, uh,

With Barclays. Please go ahead.

Great. Thanks for the questions.

I just wanted to talk on China coming in flat here things kind of improve sequentially just talk about what youre seeing there more broadly Paul.

Clearly well in orders anyway, but in clearly it seemingly stimulus-related orders where customers said, "Yeah, this is stimulus money being released," so less than $10 million? Not, not.

Forward, you talked a little bit about the stimulus.

The murderer's row of key questions, but.

How are you guys thinking about for Q&A accuray.

And ultimately are we kind of seeing some type of stabilization here or is this just kind of like a one off.

Well good questions.

And, and, and, and, um, you know, again, G. I think that's a green shoot. Um, and we'll need to again see how that continues in Q4, but I think in Q2 there was none of that, so it's a little bit better, right? So, uh, uh, China contributed, but Japan and, quite honestly, Europe were really strong in EKA Gov orders in Q3.

I wouldn't read too much into starting backwards look I wouldn't read too much into the Q4 'twenty five exit rate.

So, that's the color around the world. Yeah.

That's just a Q3 and Q4 are relatively weak on the P&L is that <unk>.

Okay, thanks. And then lastly, you just mentioned an order push-out. Can you quantify how large that was in the 1s?

The resolve of weak orders and yes, and some current new currency and tariff challenges early in the year, we can work our way through those and glaucoma.

And offset them and more than offset them by next year, but only partially this year so I wouldn't.

I would hesitate to take any given quarter of this year is modeling something for next year.

Or you mean rev? Oh, Revenue push out from. Yeah. There's a, there's a few sites that, uh, you know, have um, that that won't deliver in q1 rather than, in Q4. So that also added to some of the more conservative guidance that we now have for, for the full year, but really implied for Q4 because that's all that's left.

Okay, next

Yes.

Okay.

On China, Yes, China was a little bit better right sequentially.

Not only in academic not only some of the less than $10 million I think it was closer to six or something like that in stimulus green shoots.

US China felt a little better in Q3.

Perhaps all around that in Q2 than they were.

Probably staring down a trade or barrel and maybe now.

But maybe now this maybe that gets.

But that seems to have.

And I think I mentioned, I think I mentioned a lot. It is true that, I mean, it's always true that we get more than half the orders in a quarter in the third month of every quarter. But yes, a lot of the orders and the order improvement really became clear in September. Um, so, you know, if all of these orders that come in in July, maybe some of them would have made it into Q4, but now there is, I mean, there's some small stuff that will go into Q4. But most of the large orders are going to next year. Most of the larger orders that came in in September will be revenue in next year, I should be precise.

Even before the meeting that just happened recently that maybe the maybe the whole world is getting a little bit more optimistic that well, we know the new tariff setup and there are some there are not likely to be major trade wars.

Thank you, thanks.

The next question comes from Luke sergot with Barkley's. Please go ahead.

Hard to say right.

So China was a little better in Q3 than in Q2.

Alright, Thanks, and then turning to the spatial on demand that you guys are seeing there.

Could you talk a little bit about the <unk>.

Cadence for the instruments versus consumables and then the push here and an ability to use your existing scale as this kind of hits the core to push further with academic government customers or deeper into pharma.

Great, thanks for the questions. Um, I just want to talk on China, you coming in flat here things kind of improve, uh, sequentially. Just talk about what you're seeing there. More broadly pull forward, you talked a little bit about the stimulus. You know the the the murders row of key questions. But um you know how you guys thinking about 4 q and the X-ray.

And ultimately, are we kind of seeing some type of stabilization here? Or is this just kind of like a one-off?

Well, good questions. Um,

Yes. Good question, yes, spatial biology, with a rate slightly better orders are somewhat better or better orders in Q3, including international I believe as well.

I wouldn't read too much into starting backwards, Luke. I wouldn't read too much into the Q4 2525. Exit rate.

That's both consumables and instruments.

Remember some of the new workflows like the whole transcriptome on the cosmetics of course also will run on existing systems. They may need some upgrades, but you are not always need a new system for that but I think there was also strength in cosmetics and cell escape.

Orders. And yes, and some, you know, current new currency and and, and and tariff challenges, early in the year, we can work our way through those and come and and and and offset them and more than offset them by next year. Uh, but only partially this year. So I wouldn't

<unk>.

Thanks, Gabe is still very new so a lot of that is sort of level, we will take a little while and have a number of labs that are going to have placements of the pain scape due to this new spatial.

I would hesitate to take any given quarter this year as modeling something, for next year.

um,

<unk> makes and look at it.

Dysfunction in cancer and infectious disease before that turns into papers before that turns into revenue sets to.

That's super interesting, but it's not going to be a big contributor yet where its cause makes sense al scape are doing well.

On China. Yeah, China was a little bit better. Alright, sequentially. Um, not only in academics, not only some of the, you know, less than 10 million. I think it was closer to 6 or something like that in stimulus, green shoots. China felt a little better in Q3.

Perhaps all around, than in Q2, when they were.

Also including some of the consumables. So yes spatial biology is doing better of course, we could use more U S. Academic funding it was quite a quite depend on well.

around, probably staring down a trade war barrel and maybe now.

And, but maybe now there's, maybe that gets.

Two thirds of that is academic government and <unk> biopharma.

And.

So that strengthening in Biopharma also is good for spatial biology.

So far in the U S that's stronger than the Gulf growth.

That seems to have happened even before the meeting that just took place recently, that maybe the whole world is getting a little bit more optimistic. Well, we know the new tariffs are set up, and there are some indications that there are not likely to be major trade wars, but it’s hard to say, right? Um, so China was a little better in Q3 than in Q2.

Great. Thanks.

Okay.

And then equity welcome comes from.

<unk> Nambi with Guggenheim. Please go ahead.

Thank you for taking my question.

Shanks, Hamilton niche and marketing joining Tony diagnostics.

Diagnostics and maybe.

What do those look like next year, Ken any that would be a low double digit growth in your mind.

All right, thanks. And then I from turning to the spatial and the demand that you guys are seeing their, um, you know, if you talk a little bit about the, the uh, Cadence for the instruments versus the consumables and then, you know, the push here and and ability to use your existing scale as this kind of hits the core to push further with academic, government, customers, or deeper into Pharma.

Yes.

Agnostics is very important for US right, it's all about $500 million.

They both are based on well in 25, both in clinical microbiology and molecular diagnostics that are both in that infectious disease Division.

Um, yep. Good question. Yeah, spatial biology was our right? Um slightly better order or something but better better orders in Q3 including International I believe as well.

Um, that's both consumables and instruments.

<unk>.

Good growth good good very good growth in consumables and software and so on now in that business I think it's 60% aftermarket.

Which is.

Uh remember some of the new workflows like the whole transcript on the cosmics, of course also will run on existing systems. They may need some upgrades but you don't always need a new system for that, but I think there was also strength in Cosmic and sell scape orders.

<unk>.

Service consumables, but also database subscriptions.

So very healthy there the diagnostics business. The <unk> business, primarily is a delight. This year, it's growing nicely. It's expanding its this year 25, so it's growing its margins it's growing it's growing which is nice this year. Thanks, Jeff I don't know the exact growth rates growing somewhere in the single digits, maybe even high single digit.

It's which is individually lovely it's placements have really outperformed significantly I know you can't take placements to the bank, but next year. It will be so they had a lot of placements of their engineers and B genius stations.

Paint scape is still very new. So a lot of that is sort of uh well we'll take a little while and and and have a number of labs that are going to have placements of the paint scape, do this new spatial, um, genomics and look at, you know, dysfunction and cancer and infectious disease before that turns into papers before that turns into Revenue. That's the that that that super interesting but it's not going to be a big contributor yet whereas Cosmic and cells are doing

Doing well.

Commercial.

Synergies with broker are really working.

And they are getting into countries and into labs. They previously couldnt get so I think theyre placements is something like 20 or percent or more ahead of their business plan, which isn't revenue. This year is when these things systems, our placements under reagent rentals than it takes six months until you really have the revenue ramp, but hopefully then you have <unk>.

Also, including, uh, some of the consumables. So, yeah, spatial biology is doing better. Of course, we could use more U.S. academic funding; it was quite dependent. Well, 2/3 of that is academic government and 1/3 is biopharma, um, and and.

So that strengthening in biofarma is also good for spatial biology. And as you know, so far in the U.S., that's stronger than the economic growth.

Great, thanks.

In the next question comes from.

Five to seven years of really solid revenue and consumables pull through so that's going really well semi.

Subu Nambi with Guggenheim, please go ahead.

Semi is.

Hi.

You have to look at it in an annual basis I think we had two.

This year, we will have two quarters of fantastic orders and two quarters of naphtha fantastic orders over the year. It's all right I think it's flattish this year.

Hey uh thank you for taking my question. Um trying some of the Nisha and markets in 2026 like Diagnostics and maybe semis, what do those look like next year? Can Elite Tech be a low double digit growth in your mind.

I don't think Theres anything structural there.

And.

Revenue wise, it's been a little weaker and we expect that to improve next year.

So semi semi one really is to look at it on an annual level and it's a very nice margin contributor semi now all is approaching or is around $300 million in annual revenue. So it's also pretty meaningful for us and has very along with the diagnostics business as some of the best incremental margins.

Yeah, I did. I mean diagnostics is very important for us, right? As well, about $500 million. Um, they both are, they? They've done well in Q3 2025, both the clinical microbiology and the molecular diagnostics that are both in that infectious disease division.

Multi, biotyper.

Good growth, good, good, very good growth in consumables and software, and so on. Now, in that business, I think it's 60% aftermarket. Um, which is, you know,

So those are very core to us these are not issues for us even though we love the post genomic era both of those.

Really important core businesses.

Thank you for that Frank just a follow up can you unpack, where you saw orders incrementally positive from a profit perspective is it the lower priced equipment and then how have consumables being impacted any color you could share that.

So it's prime for the per diagnostics for molecular diagnostics and the <unk> remember they are primarily active in <unk>.

Of their ingenious and be genius stations. The, the commercial

Europe in.

Selected countries.

In Asia not in China for instance.

In parts of Africa parts of Latin America, and the strength there has been particularly in Europe.

The placement strengths that I mentioned.

And no and business.

Can you repeat the question <unk> sorry.

I thought you were referring to diagnostics.

Synergies with bruker are really working um, and they're getting into countries and into labs, they previously couldn't get. So I think their placements are something like 20 or percent or more ahead of their business plan, which isn't Revenue this year. And when these things systems are placement under reagent rentals, then it takes 6 months until you really have the revenue ramp but you know hopefully then you have 5 to 7 years of really solid revenue and consumables pull through so that's going really well semi um semi is, um,

Was there a muscle Arista quest diagnostics.

Sorry, a backing up in general the order strength that you saw this quarter Randy do you see.

<unk> is coming from from a product perspective.

Either diagnostics, our appetite of diagnostics.

And I think it's Gerald I would say the orders strengths in the third quarter was coming from larger.

Uh, you have to look at it on an annual basis. I think we had 2 this year; we'll have 2 quarters of fantastic orders and 2 quarters of not-so-fantastic orders. So, fantastic orders over the year. It's all right. I think it's flattish this year. Um, I don't think there's anything structural there. Um,

Revenue-wise, it's been a little weaker, and we expect that to improve next year.

DSP based instruments, we did have some volume, particularly coming out of our <unk>.

<unk> and <unk> businesses, which tend to have lower asps, but I would say that the bulk of the performance and the orders was particularly.

No.

Out of the European markets as well and just to clarify that we saw considerable strength in European markets.

So, semi semi won't really has to look at on an annual level and it's a, very nice margin. Contributor semi. Now, all is approaching or is around 300 million in annual revenue, so it's also a pretty meaningful for us and has very along with the Diagnostics business as some of the best incremental margins.

Actually count side, particularly so I think I can answer it now so it took me a second the strength in orders in Q3 of 25 had very little to do with diagnostics diagnostic was just humming along and its fine, but the more discreet items, where our strengths in <unk> outside of the U S Biopharma and applied.

So those are very core to us. These are not niches for us, even though we love the post-genomic era. Both of those are just really important core businesses.

Right.

Thank you for that, Frank. Um, just a follow-up. Uh, can you unpack where you saw orders incrementally positive from a product perspective? Is it the lower price equipment? And then how have consumables been impacted? Any color you could share there?

And so that is none of those include diagnostics.

Thank you for that.

Sure.

And the next question comes from Casey Woodring with Jpmorgan. Please go ahead.

So, it's prime for diagnostics, for molecular diagnostics. And the Allec, remember they are primarily active in...

Europe in u.

Great. Thank you for taking my questions.

On orders historically orders improved sequentially in <unk> in your business, but you've talked here today about some catch up in academic and government and <unk>. So can you just maybe walk through what the range of outcomes looks like an <unk> from an order exit rate perspective, how safe is it to assume order step up sequentially or are there scenarios, where an orders could be flat or down.

Selected countries uh in in Asia, like not in China for instance. Um in in in parts of Africa, parts of Latin America and the strength there has been particularly in Europe.

The placement strength that I mentioned.

No, and small business.

<unk> I have a follow up thanks.

Okay.

Can you repeat the question, super? I'm sorry. What was I? I thought they were referring to diagnostics, but...

Okay. So the.

Yes, Diagnostics.

In <unk> Gov.

Where we observed a little bit of catch up was in the U S.

I don't think that there wasn't any hold back well actually in the U S and in China, a little bit.

Yeah. Sorry. Backing up in general, the order strength that you saw this quarter. Where did you see the strength coming from, from a product perspective, either Diagnostics or outside of Diagnostics?

In the rest of the World I think that catch up I don't im not aware of that but China and the U S Gulf have been holding back.

And Thats why Q2 orders for instance in both of those geographies were weak.

So to your second part of your question Q4 is always strong so there is.

And I think Super it's Gerald. I'd say the the orders strength in the third quarter was coming from larger. Um, ASP based instruments. We did have some volume particularly coming out of our, um, Optics and axis businesses which tend to have lower asps. But I'd say the, the bulk of the performance, in the orders was particularly, um,

The question for Q4 will not be will it be up sequentially over Q3.

That's pretty much a given.

But whether we know what the trend will be year over year compared to Q4 of last year.

Got it and I hope that helps and then yes.

Definitely.

My second one just quickly on backlog I think last quarter. You noted you had six five months.

You know, uh, coming out of the European markets as well. Just to clarify that, I mean we saw considerable strength in the European markets, both in the active side. Particularly so I think I can answer it now. It took me a second. The strength in orders in Q3 of 255 had very little to do with Diagnostics. Diagnostics was just coming along, and it's fine. But the more discrete items were strengths in AAV outside of the U.S., Biofarma, and Applied.

That's right.

And you talked about that going down to five months in a normalized environment, maybe just walk through kind of how youre seeing that play out over the course of 2016. Thank you.

And so that is none of those include diagnostics.

Thank you for that.

Sure.

Well.

What I can this is gerald.

I can comment on is that.

And the next question comes from Casey Woodring with J.P. Morgan. Please go ahead.

We currently have about seven months of backlog through the third quarter of 2025, which is actually up now from the.

Six five loans recorded at the end of the second quarter.

I guess to a large extent it really depends on 26 performance is really going to depend on how we.

Now it looks like for the fourth quarter in terms of revenue performance based on our guide it looks like we will still carry considerable backlog into the 2000 2006 period.

Great. Thank you for taking my questions. Um, on orders, you know. Historically orders, improved sequentially in 4 q in your business. But you've talked to here today about some catch up in academic and government in 3 Q. So can you just maybe walk through what the range of outcomes looks like in 4 q from an order? Exit rate perspective, you know how safe is it to assume or step up sequentially or are there scenarios where in orders could be flat down, uh, in 4 Q? Then I have a follow-up. Thanks.

Okay. See. Um,

okay, so the

Right.

In Echo, gov.

Alright, great. Thank you.

Youre welcome. Thank you.

And the next question comes from Brandon <unk>.

Where we observed a little bit of catch-up was in the U.S.

<unk> with Wells Fargo. Please go ahead.

Hey, Joe Thanks for taking the questions just a couple of housekeeping items.

um,

Can you give us an updated interest expense number for the year was.

Run rate for the fourth quarter and invented a good figure to assume for 'twenty.

Is the impact of the share count from the MCT offering about 13 million shares.

In the rest of the world, I think they'd catch up. We, I'm not aware of that, but China and the U.S. and, a.k.a. Gov, have been holding back. Um, and that's why Q2 orders, for instance, in both of those geographies were weak.

Yes, Alan to answer to your last question first the answer is yes, roughly and then the first part.

So, to your second part of your question, Q4 is always strong. So there's...

We'll go through Brent and a little more on modeling on the interest because it gets a little complicated partly because we.

The question for Q4 will not be, will it be up sequentially over Q3.

You May know, we had some gains some foreign exchange gains that get covered in that line as well so somewhere in that range for two quoting on interest is correct, but we will talk more about that in our.

That's pretty much a given. Um, but whether you know what the trend will be year-over-year compared to Q4 of last year.

Modeling discussions.

Okay.

And the next question comes from Josh Waldman.

Blended research. Please go ahead.

Got it. I hope this helps and then yeah, no, no, that definitely helps. Um, and then my second 1 just quickly on backlog. I I think last quarter, you you noted yet, 6 and a half months, uh and you talked about that going down to 5 months in a normalized environment. Maybe just walk through. Kind of how you're seeing that play out over the course of 26. Thank you.

Okay.

Well, we

Two for you.

First I wondered if you could talk a bit more about what youre seeing in Europe was it primarily Aki Gov accounts that improve there or did you also see pharma and applied accounts improved as well.

what I can this is Gerald you see what I can comment on is that, you know, we currently have about 7 months of backlog, through the third quarter of 2025, which is actually up

And then I guess at this point, what's your confidence level on the sustainability and stronger Warner's I mean were there any one off funding programs or anything like that that release in the third quarter that you'll leave you I guess nervous about durability of sharp orders there.

now, from the, um,

Yes, I guess I'd say generally speaking Europe was stronger we did see strength in boots and I could go there as well as applied in Biopharma. So.

The six and a half months we quoted at the end of the second quarter, I mean, I guess to a large extent it really depends on our performance. Performance is really going to depend on how it looks like for the fourth quarter in terms of our own new performance. Based on our guide, it looks like we will still carry considerable backlog into the 2026 period.

Those are good signs and I don't think there was specific one offs related to those <unk>.

Right. Okay, great. Thank you.

You're welcome. Thank you.

Trends. So I think we're more confident but I would say we need to see Frank has repeated a couple of times here, we need to see the fourth quarter.

In the next question, comes from Brandon, collared with Wells Fargo. Please go ahead.

Order performance in order to confirm that specifically.

But all of those markets in particular on the downside European we're not being driven by one off.

Improvements or quarters.

Hey Gerald, thanks for taking the questions. Just a couple of housekeeping items. Could you give us an updated interest expense number for the year? Was the run rate for the fourth quarter? And is that a good figure to assume for 2026? Also, is the impact of the share count from the MCP offering about 13 million shares? Thanks.

Got it okay.

And then a follow up I wondered if you could provide more color on what youre seeing out of pharma I mean, it sounds like you saw sequential improvement in bookings.

Forget a few commented one orders look like year over year and as you see.

Accounts are trying to push orders through by year end or does this seem like it may be a change in how they're viewing medium term investment and research tools.

Good questions Josh This is Frank.

Yeah, I want to answer your last question first. The answer is yes, roughly. And then, um, the first part, you know, we'll go through brand in a little more modeling on the interest, because it gets a little complicated, partly because we—um, you may know we had some games, some foreign exchange games that get covered in that line as well. So somewhere in that range, the two quotations are modeling discussions.

Not aware of any particular.

Drives to get orders in placed in before the end of the.

Calendar year, so I would take this as well.

And the next question comes from Josh Walden with Cleveland Research. Please go ahead.

Biopharma having invested.

Let's now for so there was a kind of COVID-19 or post immediate post COVID-19 boom well then there was a hangover right. This was and then some concerns about most favorite nation pricing and how much capex to state they need to move things in production to the U S.

Many of them are now committed to do that over it doesn't happen overnight. So maybe that has cleared the decks a little bit to where they are investing in tools that will make drug discovery more.

2 for you. Um, first, I I wondered if you could talk a bit more about what you're seeing in in Europe, was it primarily AKA gov accounts that improved there, or did you also see Pharma and applied accounts improved as well? And then, I guess, at this point, what's your confidence level on the sustainability and stronger orders. I mean, were there any 1 off funding programs or anything like that? That released in the third quarter that you leave you, I guess nervous about the durability of stronger orders there?

Session, then give them better insights on those tools thats exactly what we provide you yes, you need DNA sequences, but you need a hell of a lot more than that to really have deeper disease biology, and then drug drug target direct mechanism of action insight so that hopefully the still very poor yields in <unk>.

Yeah, I guess I'd say, generally speaking, Europe was stronger. We did see strength in both back of, as well as applied in bio pharma. So, um,

Those are good signs, and I don't think there were specific one-offs related to those trends.

<unk> expense at length.

Bringing a successful drug to market will improve and that requires.

So, I think we're more confident, but I would say we need to see, as Frank has repeated a couple of times here, we need to see the fourth quarter order performance in order to confirm that specifically.

They are the biggest.

Integrated fans of this hypothesis of thesis are facts I would say that we that we are in the post genomic era and we need to.

But, but all of those markets in particular, on the Yakka side, European, were not being driven by one-off, um, improvements or orders.

And the disease biology, and the drug mechanisms a lot better to get better to get less attrition and rent more yield and better price discovery.

They completely agree with that they may not use the same terminology, but thats how they are investing.

Yes, I would just add.

Third quarter performance on revenue was was good okay.

Got it. Okay. Uh, and then a follow-up, I wondered if you could provide more color on what you're seeing out of Pharma. I mean, it sounds like you saw sequential improvement in bookings. I forget if you commented on what orders look like year-over-year, and does it seem like accounts are trying to push orders through by year-end? Or does this seem like maybe a change in how they're viewing medium-term investment in research tools?

The order performance from Biopharma across the Globe was strong in the third quarter from an order perspective.

Good questions. Uh, Josh, this is Frank. Um.

Not aware of any particular.

Got it thanks guys.

drives to get orders in place before the end of the

And the next question comes from Doug Schenkel with Wolfe Research. Please go ahead.

Here. So I would take this as

Biofarma having invested.

Hey, good morning, guys. Thanks for fitting me in.

Gerald.

How do we balance.

You've talked about in terms of the cost savings initiatives.

Less now for, you know, so there was a kind of a CO or post immediate post-CO boom. Well, then there was a hangover, right? This was, and then some concerns about.

And like.

You sound as good as ever on those.

You have exhibited some confidence.

About what you can do in 2026 from a margin expansion standpoint, seemingly in any growth environment. I mean at one point I think last quarter, you talked about getting 300 basis points of margin expansion next year.

Even in a flat growth environment.

On the other hand.

You increased your assumption for organic operating margin headwinds by 45 basis points for the year, which is which is pretty material with one quarter ago. So I'm just trying to figure out like how do we balance these things and is there some risk.

The benefits that you expect to occur over time are going to take a little bit longer to show up in the P&L just because of maybe.

Most favorite Nations pricing and and how much capex did they need to move things in production to the US and and many of them are now committed to do that over, you know, it doesn't happen overnight. So maybe that has has cleared the decks a little bit to where they are investing in in tools that will you know, make drug Discovery more efficient than give them better insights and those tools, that's exactly what we provide you. Yes, you need, you need sequencers. But you need a hell of a lot more than that to really have deeper disease biology and then drug drug drug Target drug mechanism of action Insight so that hopefully these still very poor yield and in enormous expense, and length of bringing a successful drug to Market will improve. And that requires, they are the biggest

The environment, we're in and the fact that I think a lot of these changes that you're making are being done outside the U S where regulate regulations can work against you.

Again, I'm just trying to think about that says as we try to set you guys up to succeed with realistic targets for 2026. Thank you.

Integrated fans of this hypothesis or thesis, or facts. I would say that we, you know, that we are in the post-genomic era, and we need to understand the disease biology and the drug mechanisms a lot better to get better, to get less attrition, and more yield in better drug discovery. So they completely agree with that. They may not use the same terminology, but that's how they're investing.

Yes.

Sure.

Just to hear from you, Doug So here's what I would say first.

Yes.

Our cost saving initiatives will be and we expect them to be at the high end of the range. We quoted is $100 million to $120 million for the fiscal year 2026, and we're fully committed to that and actually we're well on track with that 95% of the auctions.

And I would just add that the third quarter performance on Revenue was was good, okay. And the order performance from biofarma across the globe was strong in the third quarter from an order of perspective.

Got it. Thanks guys.

Needed to be taken to realize that are already.

And the next question comes from Doug, with Wolf Research. Please go ahead.

Underway.

<unk> has been fully implemented so very confident with respect to that and I think.

Hey, good morning, guys. Thanks for fitting me in. Um, Gerald, um,

More generally our expectation around margin expansion to closer to 300 is where we are.

How do we balance?

Even under relatively weaker revenue conditions for 26, that's the position we've taken and I think we're holding to that I think the issue for US as you already know Doug is if some of these.

You know what we've talked about in terms of the cost savings initiatives, um, and you know, like...

You sound as good as ever on those.

Um, you've exhibited some confidence.

Activities around cost savings do take a bit of time, just because we have to go through a process, particularly in Europe and a lot of our own.

Cost saving actions are driven around Europe because of their footprint. So there is going to be a slight likely delay in some of this as we see more of it.

Um, about what you can do in 2026 from a margin expansion standpoint. You know, seemingly in any growth environment, I mean at one point, I think last quarter you talked about getting 300 basis points of margin expansion next year.

Even in a flat growth environment.

We're hitting in the second quarter of 2026 as opposed to in the first so that doesn't but that doesn't take us off the target and let me also I mean, so we did get.

Europe, there are other economic problems and layoffs.

Um, yep. On the other hand, you know, I think you increase your assumption for organic operating margin headwinds by 45 basis points for the year, which is pretty material with one quarter to go. So I'm just trying to figure out, like, how do we balance these things and is there some risk?

Other companies. So we got very good cooperation for instance, in Germany, and France, which can be difficult from our from our workers councils and committed entrepreneur safe agreed they've approved that what we're doing is is reasonable and protects the core and all of that.

So good cooperation.

<unk> said that the Q.

Q1 will have.

So the $120 million for the year, we're very committed to that.

That the benefits that you expect to occur over time, are going to take a little bit longer to show up in the p&l just because of maybe uh, the environment we're in. And the fact that I think a lot of these changes that you're making are being done outside the US, we're regulate we're regulations can work, uh, against you. Um, again, I'm just trying to think about this as, as we, you know, try to set you guys up to succeed with realistic targets for 2026. Thank you.

And in Q1, we'll have I don't know, 90% or 95% of the run rate cost savings implemented such a few things just the way they're timed will come in in Q2, but it's not going to be a big modeling different stock or anybody else.

Yeah, sure. Nice to hear from you, Doug. So, here's what I'd say first: um,

But yes that's.

Flows in the $120 million is not some sort of a Q4 run rate thats for the full year. Thanks Erika.

And just to your earlier part of your question I mean, we did have with respect to the fourth quarter of 'twenty five we do have some mix challenges.

In the fourth quarter for 25.

In the previous year as well, so I think youre going to see some.

You did see a change in the overall guide from an organic.

Operating margin impact with respect to the fourth quarter or so.

The explanation for that Doug.

Okay I'll leave it there thank you guys.

Thank you. Thank you all.

This concludes our question and answer session I would like to turn the conference back over to Joe Oscar.

Our cost saving initiatives, um, will be and we expect them to be at the high end of the range. We quoted this 100 to 120 million for fiscal year 2026 and we're fully committed to that. And actually we're well on track with that 95% of the actions that needed to be taken to realize that are already um underway or have been fully implemented. So very confident with respect to that and I think, you know, more generally our expectation around margin expansion of closer to 300 is where we are, um, even under relatively weaker Revenue conditions for 26, that's the position we've taken and I think we're holding to that. I think the issue for us as you already know, I think Doug is, you know, some of these, um, activities around cost savings. Do take a bit of time, just because we have to go through a process particularly in Europe and a lot of our um, cost-saving actions are driven around Europe because of our footprint. So, there's

Any closing remarks.

Going to be a slight, likely delay in some of this, as we're going to see more of it.

Thank you for joining us today brokers leadership team looks forward to meeting with you in an event or speaking with you directly during the fourth quarter feel free to reach out to me to arrange any follow up have a good day.

The conference has now concluded. Thank you for attending today's presentation you may now disconnect.

Let me also, I mean, so we, we did get, you know, Europe, there are other economic problems and and layoffs, and by other companies. So we got very good cooperation, for instance, in Germany and France, which can be difficult from our from our workers councils and committed entrepreneurs, they've agreed they've approved that what we're doing is is reasonable and you know, protects the core and all of that. Um, so good cooperation.

When Gerald said that the Q1 will have,

So so the 120 million for the year, we're very committed to that um and and q1 will have, I don't know 90% or 95% of the Run rate cost savings implemented. That's right. A few things just the way they're timed, will will come in in Q2, but it's not going to be a big modeling difference, Doug or anybody else. Um, but yes, um, that's that's how it flows. And the 120 million is not some sort of a Q4 run rate that's for the full year. Exactly. Yeah. Well, and and just to to your earlier part of your question. I mean, we did have, you know, with respect to the fourth quarter of 25. We do have some mixed challenges um in the fourth quarter for 25 that we didn't see in the previous year as well. So I think you're going to see some um you did 2 years change in the overall guide from an organic um operating margin impact um with respect to to to the fourth quarter. So

That's the explanation for that, Doug.

Okay.

Thank you. Thank you all.

Gin. And now I would like to turn the conference back over to Joe Kostka for any closing remarks.

Thank you for joining us today. Bruker's leadership team looks forward to meeting with you at an event or speaking with you directly during the fourth quarter. Feel free to reach out to me to arrange any follow-up. Have a good day.

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.